TWD 79.5
(-3.52%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 1.55 TWD | 108.75% |
2022 | 0.80 TWD | 42.86% |
2021 | 0.56 TWD | 107.41% |
2020 | 0.27 TWD | 107.69% |
2019 | 0.13 TWD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.47 TWD | 327.27% |
2024 Q2 | 0.35 TWD | -29.79% |
2023 Q4 | 0.11 TWD | -72.5% |
2023 FY | - TWD | 108.75% |
2023 Q3 | 0.40 TWD | -40.3% |
2023 Q2 | 0.67 TWD | 36.73% |
2023 Q1 | 0.49 TWD | 133.33% |
2022 FY | - TWD | 42.86% |
2022 Q4 | 0.21 TWD | 0.0% |
2021 FY | - TWD | 107.41% |
2020 FY | - TWD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
DIVA Laboratories, Ltd. | 1.25 TWD | -24.0% |
Genetics Generation Advancement Corp. | 1.07 TWD | -44.86% |
Welgene Biotech Co.,Ltd. | -0.11 TWD | 1509.091% |
Puriblood Medical Co., Ltd. | -3.63 TWD | 142.7% |
TFBS Bioscience Inc. | 0.17 TWD | -811.765% |